VEGFA and breast neoplasm: Dual inhibition of Ang-2 and VEGF-A significantly reduced pathological neovascularisation and vessel density by >50% (P = 0.04) versus IgG controls, and enhanced pericyte coverage on blood vessels versus IgG controls and anti–Ang-2 or anti–VEGF-A monotherapy by approximately two-fold (P ≤ 0.04) in a human breast tumour-bearing mouse model.